Target intelligence / Profile preview

Transmembrane inner ear expressed protein (TMIE)

Target
TMIE
Molecular classification
Other (evolutionarily conserved membrane protein), Auxiliary subunit of ion channel complex, Not classified as ion channel, transporter, receptor, or enzyme in the classic sense, but as an accessory/auxiliary subunit of the mechanotransducer complex[2][5]
01

Overview

Transmembrane inner ear expressed protein (TMIE) is a small, evolutionarily conserved membrane protein with two transmembrane domains separated by an extracellular loop, located predominantly at the tips of stereocilia in cochlear hair cells[1][2][5]. TMIE serves as an essential auxiliary component of the mechanotransducer (MET) channel complex, which converts mechanical sound vibrations into electrical signals in the auditory system[2][5]. Mutations in the TMIE gene cause severe to profound congenital or prelingual non-syndromic sensorineural hearing loss in humans (DFNB6), and homologs in mice and zebrafish confirm its universal and vital role in hair cell function and auditory mechanotransduction[1][3][4]. TMIE is not a therapeutic receptor, enzyme, transporter, or ion channel itself, but it is critical for the function of these complexes in sensory hair cells, serving mainly as an accessory protein facilitating proper assembly, localization, or function of the MET channel[2][5]. No drugs currently target TMIE, so it is not considered a direct therapeutic target at this time.

Other names
TMIEDFNB6 proteinTransmembrane inner ear proteinTransmembrane inner ear expressed proteinTransmembrane inner ear
02

Mechanism of action

Currently, no drugs are known to target TMIE; therefore, mechanisms of action are not described.

03

Biological functions

Auditory mechanotransduction (conversion of mechanical stimuli to electrical signals in cochlear hair cells)[1][2][5]Maintenance and maturation of sensory hair cells, especially stereocilia bundles[1][2][4]Essential for normal development of the cochlea and inner ear sensory structures[3][4]Supports hearing function[1][2][3][4]
04

Disease associations

Hereditary deafness (DFNB6)[1][2]Non-syndromic sensorineural hearing loss (autosomal recessive)[1][2]Vestibular dysfunction (in animal models)[3][4]
05

Safety considerations

Therapeutic targeting not established; genetic therapy might present risks inherent to cochlear gene therapy in the future, but such applications are not current standard.

Beyond the preview

Go deeper on Transmembrane inner ear expressed protein (TMIE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane inner ear expressed protein (TMIE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call